高级检索
邵蓉, 殷天红. 美国药品审评付费制度对我国加快药品审评的启示[J]. 中国药科大学学报, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305
引用本文: 邵蓉, 殷天红. 美国药品审评付费制度对我国加快药品审评的启示[J]. 中国药科大学学报, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305
SHAO Rong, YIN Tianhong. Charging system in US PDUFA with reference to speeding up drug evaluation process of China[J]. Journal of China Pharmaceutical University, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305
Citation: SHAO Rong, YIN Tianhong. Charging system in US PDUFA with reference to speeding up drug evaluation process of China[J]. Journal of China Pharmaceutical University, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305

美国药品审评付费制度对我国加快药品审评的启示

Charging system in US PDUFA with reference to speeding up drug evaluation process of China

  • 摘要: 目前我国药品审评时间长的问题已经引起业界广泛关注,药企付费以加快药品审评已成为制药行业的一致呼声。本文通过分析美国药品审评付费制度以及实施后产生的利与弊,结合我国药品审评现状,探讨如何运用收费方式加快我国药品审评。

     

    Abstract: The lengthy drug evaluation period has aroused wide attention. Fee payment by pharmaceutical enterprise has become common consensus of pharmaceutical industry. This paper analysies the advantages and disadvantages of drug evaluation charging system in the US with its reference to the current situation of drug evaluation in China, with an attempt to accelerate evaluation process by properly adopting the charging system in China.

     

/

返回文章
返回